Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors. The company also has five oncology programs in the discovery stage that are designed to target components of the MAPK or mTOR pathway; and two discovery stage neuroscience programs. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts. Immuneering Corporation was a former subsidiary of Teva Pharmaceutical Industries Limited.
P/B ratio for Immuneering Corporation (IMRX)
P/B ratio as of 2023: 2.31
According to Immuneering Corporation's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 2.31. At the end of 2022 the company had a P/B ratio of 1.17.
P/B ratio history for Immuneering Corporation from 2019 to 2023
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2023 | 2.31 |
| 2022 | 1.17 |
| 2021 | 2.73 |
| 2020 | -19.96 |
| 2019 | -68.76 |